Stockreport

Immunovant Provides Update on Graves' Disease Development Program [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12 Strong correlation observed between degree of IgG lowering and cl [Read more]